

RESEARCH ARTICLE

Open Access

# Functional associations among G protein-coupled neurotransmitter receptors in the human brain

Skirmantas Janušonis

## Abstract

**Background:** The activity of neurons is controlled by groups of neurotransmitter receptors rather than by individual receptors. Experimental studies have investigated some receptor interactions, but currently little information is available about transcriptional associations among receptors at the whole-brain level.

**Results:** A total of 4950 correlations between 100 G protein-coupled neurotransmitter receptors were examined across 169 brain regions in the human brain using expression data published in the Allen Human Brain Atlas. A large number of highly significant correlations were found, many of which have not been investigated in hypothesis-driven studies. The highest positive and negative correlations of each receptor are reported, which can facilitate the construction of receptor sets likely to be affected by altered transcription of one receptor (such sets always exist, but their members are difficult to predict). A graph analysis isolated two large receptor communities, within each of which receptor mRNA levels were strongly cross-correlated.

**Conclusions:** The presented systematic analysis shows that the mRNA levels of many G protein-coupled receptors are interdependent. This finding is not unexpected, since the brain is a highly integrated complex system. However, the analysis also revealed two novel properties of global brain structure. First, receptor correlations are described by a simple statistical distribution, which suggests that receptor interactions may be guided by qualitatively similar processes. Second, receptors appear to form two large functional communities, which might be differentially affected in brain disorders.

**Keywords:** Human brain, G protein-coupled receptor, mRNA, Network, Communities, Receptor sets

## Background

A typical neuron receives thousands of synaptic contacts [1], and each postsynaptic site can express a number of neurotransmitter receptors. Since neurons integrate signals from all receptors on their surface, their activity is determined by receptor sets and not by individual receptors.

Functional receptor groups explain why a constitutive null-mutation of a neurotransmitter receptor often produces a mild phenotype, even when the receptor is known to be important in specific brain functions [2-10]. Such minor functional effects can be explained by compensatory mechanisms in the developing brain, which at least partially depend on receptors that detect other neurotransmitters [4,11].

Similarly, the absence of an entire neurotransmitter may not have a major effect on brain development and function. Serotonin (5-hydroxytryptamine, 5-HT) is an extremely abundant neurotransmitter in the brain: by some estimates, the density of serotonergic varicosities in the rat cerebral cortex is around  $6 \cdot 10^6/\text{mm}^3$ , with each cortical neuron receiving some 200 varicosities [12]. The density of serotonergic projections may exceed that of the brain capillary system [13,14] and must carry a significant energetic cost. However, genetic mutations and pharmacological manipulations that eliminate virtually all 5-HT in the brain produce only subtle behavioral alterations, with no gross morphological or cellular changes [15-18]. Abnormally low dopamine levels in the brain can be nearly asymptomatic until around 50-80% of the substantia nigra neurons are lost [19], and ablation of dopaminergic neurons in neonatal rats does not result in any significant motor dysfunctions [20,21]. A lack of norepinephrine due to a genetic mutation in the dopamine- $\beta$ -hydroxylase gene

Correspondence: skirmantas.janusonis@psych.ucsb.edu  
Department of Psychological and Brain Sciences, University of California,  
Santa Barbara, CA, USA

produces an unremarkable neurological phenotype in humans [22,23]. Mammalian thalamic nuclei can function normally in the virtual absence of GABAergic interneurons, as has been shown in mice and rats [24,25]. Experimental evidence shows that the lack of one neurotransmitter can be compensated for by changes in other neurotransmitters: for example, serotonergic processes have been shown to permanently extend into brain areas previously occupied by dopaminergic terminals [26], and serotonin and/or dopamine may compensate for the lack of norepinephrine [27,28]. It should be noted that at least some adult neurons have the flexibility to switch from one neurotransmitter to another in response to the environment [29].

These findings suggest that biological information in the brain is coded not by individual neurotransmitters or their receptors, but by finely-tuned neurotransmitter-receptor sets. While this hypothesis does not require that the receptors be physically linked, it is supported by the unexpected abundance of heteromeric receptor complexes [30,31]. For example, the serotonin 5-HT<sub>2A</sub> receptor can form complexes with the metabotropic glutamate mGluR<sub>2</sub> receptor [32] and the dopamine D<sub>2</sub> receptor [33], which may play a major role in the action of antipsychotic drugs and hallucinogens. A heterocomplex is more than the sum of its individual receptors, since heteromerization can alter receptor mobility at the neuron surface, downstream signaling, and intracellular trafficking [32,34].

Understanding neurotransmitter receptor sets will require new analytical and theoretical approaches. Functionally complete receptor sets have to be isolated and their dynamic properties investigated in specific brain regions and in individual cells [35]. While these studies pose technical challenges, they are likely to lead to major theoretical simplifications. Some researchers have already used this approach with considerable success [36-38]. As a further step toward this goal, the present study used the Allen Human Brain Atlas [39,40] to examine mRNA expression associations among nearly all known G protein-coupled neurotransmitter receptors in the human brain.

## Results

The analysis used the mRNA expression data of 100 G protein-coupled receptors (Table 1) in 169 regions of six normal human brains presently available in the Allen Brain Atlas database (Figure 1). The mRNA amounts of many receptor pairs were very strongly correlated (Figure 2). The five strongest positive and negative correlations of each receptor are given in Table 2. The distribution of all 4950 correlations had a nearly symmetric shape, with a single mode shifted toward the positive values (Figure 3A, B). This distribution failed normality tests (Figure 3A; the Kolmogorov-Smirnov test:  $D = 0.024$ ,

$p < 0.01$ ; the Shapiro-Wilk test:  $W = 0.995$ ,  $p < 0.01$ ), but was well described by the beta distribution with the same range, mean and variance (the shape parameters  $\alpha = 3.51$  and  $\beta = 3.32$ ) (Figure 3B;  $D = 0.015$ ,  $p = 0.209$ ). The distributions of several functionally meaningful subsets were not significantly different from the complete set (in each pair, both receptors represent the same neurotransmitter (Figure 3C):  $D = 0.076$ ,  $p = 0.169$ ); (in each pair, the receptors represent different neurotransmitters (Figure 3D):  $D = 0.004$ ,  $p = 1$ ); (in each pair, both receptors have the same G protein-coupling (Figure 3E):  $D = 0.015$ ,  $p = 0.950$ ); (in each pair, the receptors have different G protein-couplings (Figure 3F):  $D = 0.007$ ,  $p = 1$ )).

All statistically significant correlations among the receptors were plotted as a graph (Figure 4A). The nociceptin receptor (ORL-1) had the highest vertex degree (connectivity), due to its significant correlations with 58 receptors (Figure 4B). The largest clique consisted of 18 completely interconnected vertices: the glutamate receptors mGluR<sub>2</sub>, mGluR<sub>4</sub>, mGluR<sub>7</sub>, the adrenergic receptors  $\alpha_{1B}$ ,  $\alpha_{1D}$ ,  $\beta_1$ , the serotonin receptors 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>2A</sub>, the cholinergic receptors M<sub>1</sub>, M<sub>3</sub>, the histamine receptors H<sub>1</sub>, H<sub>2</sub>, the melanin-concentrating hormone MCH<sub>1</sub>, the neuropeptide Y receptors Y<sub>1</sub>, Y<sub>5</sub>, the nociceptin receptor (ORL-1), and the somatostatin receptor SST<sub>1</sub>. The distribution of the vertex degrees (the number of links originating in each receptor) appeared to be bimodal and did not follow the power law that is often observed in natural networks with high functional connectivity (Figure 4A, inset). However, a recent study has shown that a bimodal degree distribution can emerge in robust networks [41].

Next, the obtained correlation information was used to examine whether some receptors groups are more tightly interlinked than other receptors or, more precisely, whether the graph (Figure 4A) can be broken down into distinct receptor communities. Two community detection methods were used: the modularity algorithm and the clique percolation algorithm [42]. The modularity method revealed two major receptor communities (Figure 5). As recommended by Palla et al. [42], the clique percolation method was optimized using several correlation thresholds ( $T = 0.5, 0.6, 0.7, 0.8$ , and  $0.9$ ) and  $k$ -cliques of several sizes. The best separation was achieved with  $T = 0.6$  and  $k = 4$ , which again revealed two distinct receptor communities (Figure 6). With the exception of one receptor (BDKRB2), the separation among the receptors was identical to the one obtained with the modularity method. Since the clique percolation method used more stringent criteria, it excluded some more weakly correlated receptors (importantly, they were not placed in the opposite community). These analyses suggest that the human brain has two functional receptor communities, within each of which the mRNA levels are strongly correlated and can potentially affect each other. The first community contains

**Table 1 The analyzed G protein-coupled receptors**

Number	Neurotransmitter	Receptor	Gene	Coupling	Median inter-subject correlation
1	Glutamate	mGluR1	GRM1	Gq	0.91
2	Glutamate	mGluR2	GRM2	Gi	0.37
3	Glutamate	mGluR3	GRM3	Gi	0.82
4	Glutamate	mGluR4	GRM4	Gi	0.94
5	Glutamate	mGluR5	GRM5	Gq	0.92
6	Glutamate	mGluR6	GRM6	Gi	0.12
7	Glutamate	mGluR7	GRM7	Gi	0.89
8	Glutamate	mGluR8	GRM8	Gi	0.45
9	GABA	GABABR1	GABBR1	Gi	0.78
10	GABA	GABABR2	GABBR2	Gi	0.89
11	Dopamine	D1	DRD1	Gs	0.91
12	Dopamine	D2	DRD2	Gi	0.89
13	Dopamine	D3	DRD3	Gi	0.69
14	Dopamine	D4	DRD4	Gi	0.03
15	Dopamine	D5	DRD5	Gs	0.83
16	Adrenergic	$\alpha$ 1A	ADRA1A	Gq	0.76
17	Adrenergic	$\alpha$ 1B	ADRA1B	Gq	0.87
18	Adrenergic	$\alpha$ 1D	ADRA1D	Gq	0.79
19	Adrenergic	$\alpha$ 2A	ADRA2A	Gi	0.62
20	Adrenergic	$\alpha$ 2B	ADRA2B	Gi	0.31
21	Adrenergic	$\alpha$ 2C	ADRA2C	Gi	0.64
22	Adrenergic	$\beta$ 1	ADRB1	Gs	0.59
23	Adrenergic	$\beta$ 2	ADRB2	Gs	0.67
24	Adrenergic	$\beta$ 3	ADRB3	Gs/Gi	0.15
25	Serotonin	5-HT1A	HTR1A	Gi	0.86
26	Serotonin	5-HT1B	HTR1B	Gi	0.38
27	Serotonin	5-HT1D	HTR1D	Gi	0.79
28	Serotonin	5-HT1E	HTR1E	Gi	0.82
29	Serotonin	5-HT1F	HTR1F	Gi	0.90
30	Serotonin	5-HT2A	HTR2A	Gq	0.95
31	Serotonin	5-HT2B	HTR2B	Gq	0.12
32	Serotonin	5-HT2C	HTR2C	Gq	0.92
33	Serotonin	5-HT4	HTR4	Gs	0.89
34	Serotonin	5-HT5A	HTR5A	Gs	0.89
35	Serotonin	5-HT6	HTR6	Gs	0.21
36	Serotonin	5-HT7	HTR7	Gs	0.89
37	Cholinergic	M1	CHRM1	Gq	0.53
38	Cholinergic	M2	CHRM2	Gi	0.91
39	Cholinergic	M3	CHRM3	Gq	0.96
40	Cholinergic	M4	CHRM4	Gi	0.53
41	Cholinergic	M5	CHRM5	Gq	0.63
42	Histamine	H1	HRH1	Gq	0.82
43	Histamine	H2	HRH2	Gs	0.69
44	Histamine	H3	HRH3	Gi	0.66

**Table 1 The analyzed G protein-coupled receptors (Continued)**

45	Histamine	H4	HRH4	Gi	0.09
46	Bradykinin	B1	BDKRB1	Gq	0.69
47	Bradykinin	B2	BDKRB2	Gq	0.61
48	Cholecystokinin	CCK1	CCKAR	Gq	0.46
49	Cholecystokinin	CCK2	CCKBR	Gq	0.94
50	CRH	CRF1	CRHR1	Gs	0.65
51	CRH	CRF2	CRHR2	Gs	0.35
52	Galanin	Gal1	GALR1	Gi	0.74
53	Galanin	Gal2	GALR2	Gi/Gq	0.54
54	Galanin	Gal3	GALR3	Gi	0.08
55	MCH	MCH1	MCHR1	Gi	0.70
56	MCH	MCH2	MCHR2	Gq	0.93
57	MSH	MC1	MC1R	Gs	0.73
58	MSH	MC2	MC2R	Gs	0.10
59	MSH	MC3	MC3R	Gs	0.40
60	MSH	MC4	MC4R	Gs	0.49
61	MSH	MC5	MC5R	Gs	0.04
62	NPY	Y1	NPY1R	Gi	0.91
63	NPY	Y2	NPY2R	Gi	0.74
64	NPY	Y4	PPYR1	Gi	0.18
65	NPY	Y5	NPY5R	Gi	0.86
66	NPY	Y6	NPY6R	Gi	0.36
67	Neurotensin	NT1	NTSR1	Gq	0.48
68	Neurotensin	NT2	NTSR2	Gq	0.81
69	Opioid	μ	OPRM1	Gi	0.84
70	Opioid	δ	OPRD1	Gi	0.25
71	Opioid	κ	OPRK1	Gi	0.67
72	Nociceptin	ORL-1	OPRL1	Gi	0.81
73	Orexin	OX1	HCRTR1	Gq	0.82
74	Orexin	OX2	HCRTR1	Gi	0.64
75	Oxytocin	OT	OXTR	Gq	0.75
76	Somatostatin	SST1	SSTR1	Gi	0.81
77	Somatostatin	SST2	SSTR2	Gi	0.91
78	Somatostatin	SST3	SSTR3	Gi	0.28
79	Somatostatin	SST4	SSTR4	Gi	0.07
80	Somatostatin	SST5	SSTR5	Gi	0.16
81	Tachykinin	NK1	TACR1	Gq	0.55
82	Tachykinin	NK2	TACR2	Gq	0.34
83	Tachykinin	NK3	TACR3	Gq	0.81
84	TRH	TRHR	TRHR	Gq	0.79
85	VIP	VPAC1	VIPR1	Gs	0.86
86	VIP	VPAC2	VIPR2	Gs	0.77
87	Vasopressin	V1a	AVPR1A	Gq	0.34
88	Vasopressin	V1b	AVPR1B	Gq	0.04
89	Vasopressin	V2	AVPR2	Gs	0.16

**Table 1 The analyzed G protein-coupled receptors (Continued)**

90	Adenosine	A1	ADORA1	Gi	0.66
91	Adenosine	A2A	ADORA2A	Gs	0.87
92	Adenosine	A2B	ADORA2B	Gs	0.57
93	Adenosine	A3	ADORA3	Gi	0.37
94	Purine	P2Y1	P2RY1	Gq	0.72
95	Purine	P2Y2	P2RY2	Gi/Gq	0.37
96	Purine	P2Y4	P2RY4	Gi/Gq	0.00
97	Purine	P2Y6	P2RY6	Gq	0.32
98	Purine	P2Y11	P2RY11	Gq	0.34
99	Cannabinoid	CB1	CNR1	Gi	0.90
100	Cannabinoid	CB2	CNR2	Gi	0.46

The inter-subject correlations were obtained from 6 subjects (15 cross-correlations).

the glutamate receptor mGluR<sub>1</sub>, the dopamine receptor D<sub>2</sub>, the adrenergic receptor β<sub>3</sub>, the serotonin receptors 5-HT<sub>1B</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>6</sub>, the cholinergic receptors M<sub>4</sub> and M<sub>5</sub>, the bradykinin receptors B<sub>1</sub> and B<sub>2</sub>, the cholecystokin receptor CCK<sub>2</sub>, the CRH receptor CRF<sub>1</sub>, the galanin receptor Gal<sub>2</sub>, the NPY receptor Y<sub>6</sub>, the neurotensin receptor NT<sub>2</sub>, the oxytocin receptor, the somatostatin receptors SST<sub>3</sub> and SST<sub>4</sub>, the tachykinin receptor NK<sub>2</sub>, the VIP receptor VPAC<sub>1</sub>, the purine receptor P2Y<sub>11</sub>, and the cannabinoid receptor CB<sub>2</sub>. The second community contains the glutamate receptors mGluR<sub>2</sub>, mGluR<sub>5</sub>, mGluR<sub>7</sub>, the dopamine receptor D<sub>1</sub>, the adrenergic receptors α<sub>1B</sub>, α<sub>1D</sub>, β<sub>1</sub>, the serotonin receptors 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>4</sub>, the cholinergic receptors M<sub>1</sub> and M<sub>3</sub>, the histamine receptors H<sub>1</sub> and H<sub>2</sub>, the MCH receptors MCH<sub>1</sub> and MCH<sub>2</sub>, the NPY receptors Y<sub>1</sub> and Y<sub>5</sub>, the nociceptin receptor (ORL-1), the somatostatin receptor SST<sub>1</sub>, and the VIP receptor VPAC<sub>2</sub>.


## Discussion

The Allen Human Brain Atlas is a relatively new database [39,40] that continues to be updated and refined. In the absence of generally accepted standards for how gene expression data should be normalized and presented, the published expression values should be treated with caution. The expression of many receptors is highly consistent across individuals, but some receptors show a high degree of variability (Table 1). Among them is the dopamine receptor 4 (coded by the DRD4 gene), which has been extensively studied because of a functionally important polymorphism in its exon 3 [43-47]. The origin of its inconsistent distribution across individuals is not clear and may be due to either unreliable detection or true expression differences in the population. Notably, no relationship has been established between the DRD4 alleles and their mRNA levels [48].

Caution should also be exercised in the interpretation of mRNA levels that show a consistent pattern across

the subjects. For many receptors, the relationship between the mRNA and protein quantities is often poorly understood, and a change in one of these measures may not indicate a change in the other. A recent large-scale study has shown that, on average, mRNA levels explain around 40% of the variability in protein levels, and that the abundance of a protein is predominantly controlled by translation [49]. In addition, many neurotransmitter receptors operate in two different signaling modes: at the membrane surface through G-proteins and, when internalized, in an arrestin-dependent fashion [50]. Neurotransmitter receptor genes can produce several mRNA splice variants, some of which may be constitutively active (ligand-independent) [51], or have different internalization properties [52]. Also, protein molecules can be phosphorylated, glycosylated, and undergo other modifications [50,53-55]. These post-translational processes place severe limitations on functional inferences from mRNA data. On the other hand, mRNA quantification allows a high degree of specificity, which remains difficult to achieve in protein analyses. Post-translational modifications of protein molecules and the absence of specific antibodies for a number of neurotransmitter receptors (contrary to the claims of manufacturers) currently do not allow large scale quantifications of proteins in the entire brain. Even though the protein data remain limited, Table 1 provides information about the possible inter-individual variability of the mRNA levels of nearly all neurotransmitter receptors and will facilitate the interpretation of completed and future studies.

The analyzed mRNA levels in brain structures reflect the cumulative gene expression in several types of neuronal and glial cells, with a possible contribution from endothelial and ependymal cells. This lack of spatial precision makes the obtained results too “coarse” for the modeling of local neural circuits. However, an association between the abundance of two receptors over many brain regions is functionally meaningful, just as biologically




**Figure 1** The mRNA expression profiles of six neurotransmitter receptors. The horizontal axis represents the 169 brain regions and the vertical axis represents the mRNA amounts (averaged across the probes and subjects). Since the numerical mRNA values are normalized and relative, they are not indicated on the vertical axis (for all six genes, it ranges from -2 to 2). Note high similarity between some of the profiles (e.g., mGluR<sub>1</sub> and CRF<sub>1</sub>, 5-HT<sub>2A</sub> and H<sub>1</sub>).

meaningful information can be obtained from the correlation between the population numbers of two species across geographic areas (even if the species do not directly interact). Hypofunction or hyperfunction of a receptor in a class of cells is likely to affect the activity of their local neuroecosystems, which may induce changes in the expression of receptors in other cells [56]. Therefore, estimates of the most likely associations among receptors are important for the interpretation of receptor knockout models, as well as for the prediction of changes in other receptors associated with pharmacological targeting of a specific neurotransmitter receptor [57,58]. At present, no comprehensive quantitative analysis exists to facilitate these theoretical considerations, and published data are likely to be biased by hypothesis-driven approaches, funding agency priorities, and attracting nodes in researcher networks. While the current analysis is a step forward, major theoretical breakthroughs can be expected when technical capabilities become sufficiently advanced to dynamically monitor entire receptor sets in single neurons and glial cells [35].

Currently little information is available about the correlation between the mRNA levels of receptors that form heteromeric complexes. Among them, the complex between the metabotropic glutamate receptor mGluR<sub>2</sub> and the serotonin receptor 5-HT<sub>2A</sub> has been particularly well studied, partly because of its potential importance in schizophrenia and other related brain disorders [32,59,60]. It has been recently reported that the disruption of 5-HT<sub>2A</sub> receptor-dependent signaling can suppress mGluR<sub>2</sub> transcription through epigenetic modifications in the mGluR<sub>2</sub> gene promoter [61]. The present analysis found a highly significant positive correlation between the mRNA levels of these two receptors (0.49). However, mGluR<sub>2</sub> had the highest positive correlations with the nociceptin receptor (ORL-1), the adrenergic  $\alpha_{1D}$  and  $\beta_2$  receptors, the histamine H<sub>2</sub> receptor, and the purine P2Y<sub>6</sub> receptor; and the 5-HT<sub>2A</sub> receptor had the highest positive correlations with the histamine H<sub>1</sub> receptor (Figure 1), the serotonin 5-HT<sub>1F</sub> receptor, the muscarinic cholinergic M<sub>3</sub> receptor, and the melanin-concentrating hormone receptors MCH<sub>1</sub> and MCH<sub>2</sub> (Table 2).

Two receptor communities were extracted from the data (Figures 5 and 6). There are many neural circuits where these receptors interact, but it remains unclear whether the entire communities can be assigned a biologically



**Figure 2** The scatter plots of the six most strongly correlated receptor pairs (out of the 4950 pairs). Each point represents the mRNA amounts (averaged across the probes and subjects) of the two receptors in one of the 169 brain regions. Considerable clustering is apparent, which indicates that in most brain regions the mRNA levels of the two receptors are either low or high simultaneously, with few regions in between. All correlations are significant at  $p < 10^{-15}$ .

meaningful role. It should be noted that many of the receptors in the two “minimal” communities (Figure 6) control global brain functions, such as wakefulness and sleep [62]. The two communities can be differentially affected in some brain disorders. For example, the 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>

and 5-HT<sub>4</sub> receptors belong to the same community (Figure 6) and are expressed by neurons in the medial prefrontal cortex (mPFC) that project to the dorsal raphe nucleus and control serotonin release [63,64]. Altered activity of these neurons has been implicated in mood

**Table 2 The five strongest positive and negative correlations of each receptor with other receptors, calculated using 169 brain regions**

1) mGluR1		2) mGluR2		3) mGluR3		4) mGluR4		5) mGluR5		6) mGluR6	
50	0.80	72	0.65	90	0.72	57	0.93	72	0.82	88	0.63
4	0.74	18	0.64	43	0.62	50	0.76	39	0.81	4	0.63
57	0.71	43	0.63	23	0.51	1	0.74	65	0.80	57	0.60
46	0.65	97	0.60	22	0.50	46	0.68	7	0.79	50	0.54
98	0.63	23	0.58	93	0.49	47	0.66	43	0.76	47	0.53
68	-0.51	69	-0.33	6	-0.22	62	-0.64	50	-0.32	42	-0.34
52	-0.53	80	-0.34	59	-0.26	39	-0.64	46	-0.39	39	-0.35
75	-0.54	46	-0.35	69	-0.27	76	-0.68	47	-0.49	32	-0.39
40	-0.55	57	-0.55	57	-0.31	30	-0.72	57	-0.57	22	-0.42
32	-0.63	4	-0.56	4	-0.32	42	-0.76	4	-0.58	23	-0.50
7) mGluR7		8) mGluR8		9) GABA1		10) GABA2		11) D1		12) D2	
5	0.79	15	0.57	10	0.63	9	0.63	65	0.74	40	0.71
72	0.76	74	0.52	92	0.57	49	0.58	21	0.74	35	0.69
62	0.65	53	0.47	1	0.49	17	0.58	22	0.71	68	0.67
65	0.65	40	0.47	98	0.49	39	0.56	43	0.70	75	0.66
42	0.64	38	0.46	50	0.47	34	0.56	33	0.69	100	0.66
50	-0.40	50	-0.34	8	-0.25	54	-0.27	4	-0.31	50	-0.49
57	-0.50	4	-0.35	32	-0.25	27	-0.28	47	-0.32	77	-0.50
46	-0.50	98	-0.39	41	-0.28	12	-0.31	69	-0.32	46	-0.60
4	-0.52	1	-0.39	14	-0.31	83	-0.32	57	-0.34	85	-0.67
47	-0.59	57	-0.43	53	-0.31	32	-0.41	54	-0.35	49	-0.70
13) D3		14) D4		15) D5		16) α1A		17) α1B		18) α1D	
91	0.68	51	0.40	72	0.66	84	0.52	56	0.63	72	0.76
27	0.65	70	0.22	75	0.63	63	0.38	39	0.63	36	0.72
33	0.64	98	0.18	68	0.62	7	0.31	30	0.63	5	0.71
21	0.63	97	0.17	52	0.61	94	0.26	42	0.59	2	0.64
12	0.62	46	0.17	82	0.60	79	0.26	55	0.59	39	0.64
34	-0.19	7	-0.29	1	-0.47	39	-0.14	35	-0.29	47	-0.39
10	-0.22	9	-0.31	46	-0.49	74	-0.16	57	-0.30	80	-0.43
49	-0.24	94	-0.31	50	-0.50	90	-0.18	54	-0.30	46	-0.45
46	-0.27	68	-0.34	57	-0.60	20	-0.22	64	-0.30	4	-0.53
50	-0.30	60	-0.35	4	-0.60	44	-0.31	4	-0.35	57	-0.54
19) α2A		20) α2B		21) α2C		22) β1		23) β2		24) β3	
73	0.63	91	0.50	11	0.74	29	0.74	93	0.68	78	0.69
81	0.50	13	0.43	33	0.67	11	0.71	100	0.62	79	0.67
83	0.49	12	0.42	91	0.65	39	0.71	68	0.60	100	0.63
7	0.48	35	0.40	27	0.65	37	0.69	97	0.59	82	0.61
52	0.47	43	0.33	13	0.63	56	0.69	40	0.58	89	0.57
91	-0.27	80	-0.24	57	-0.25	47	-0.44	6	-0.50	77	-0.19
4	-0.27	49	-0.27	47	-0.26	54	-0.44	85	-0.53	98	-0.20
47	-0.29	25	-0.31	1	-0.29	69	-0.45	34	-0.56	56	-0.22
50	-0.30	34	-0.32	46	-0.32	57	-0.50	4	-0.57	85	-0.30
46	-0.33	77	-0.33	50	-0.34	4	-0.53	57	-0.59	49	-0.31



**Table 2 The five strongest positive and negative correlations of each receptor with other receptors, calculated using 169 brain regions (Continued)**

25) 5-HT1A		26) 5-HT1B		27) 5-HT1D		28) 5-HT1E		29) 5-HT1F		30) 5-HT2A	
39	0.66	40	0.67	21	0.65	65	0.62	56	0.87	42	0.84
62	0.64	100	0.61	13	0.65	5	0.58	30	0.83	29	0.83
42	0.64	82	0.61	94	0.63	62	0.56	86	0.80	39	0.80
30	0.64	78	0.61	40	0.60	39	0.55	55	0.78	55	0.80
7	0.62	35	0.60	33	0.59	43	0.53	39	0.78	56	0.76
20	-0.31	1	-0.30	49	-0.30	14	-0.17	66	-0.35	54	-0.40
47	-0.35	98	-0.32	98	-0.32	95	-0.19	69	-0.39	1	-0.43
54	-0.35	49	-0.38	1	-0.32	57	-0.24	57	-0.46	47	-0.54
57	-0.49	85	-0.39	46	-0.44	4	-0.25	54	-0.48	57	-0.71
4	-0.51	46	-0.46	50	-0.46	54	-0.30	4	-0.49	4	-0.72
31) 5-HT2B		32) 5-HT2C		33) 5-HT4		34) 5-HT5A		35) 5-HT6		36) 5-HT7	
61	0.54	75	0.70	65	0.79	85	0.63	12	0.69	18	0.72
35	0.54	68	0.64	5	0.71	49	0.63	40	0.65	72	0.72
45	0.53	94	0.63	11	0.69	77	0.59	100	0.63	38	0.65
58	0.51	12	0.61	21	0.67	1	0.56	26	0.60	7	0.60
88	0.48	40	0.60	62	0.67	10	0.56	27	0.56	68	0.59
62	-0.16	85	-0.61	46	-0.45	40	-0.44	46	-0.33	57	-0.46
17	-0.18	1	-0.63	57	-0.48	78	-0.47	77	-0.35	80	-0.47
49	-0.21	98	-0.64	50	-0.49	95	-0.47	56	-0.39	49	-0.49
85	-0.21	46	-0.70	4	-0.50	100	-0.54	85	-0.50	85	-0.61
56	-0.24	50	-0.76	47	-0.50	23	-0.56	49	-0.54	46	-0.62
37) M1		38) M2		39) M3		40) M4		41) M5		42) H1	
43	0.73	36	0.65	5	0.81	12	0.71	75	0.80	30	0.84
39	0.70	72	0.63	30	0.80	100	0.70	53	0.65	39	0.80
22	0.69	15	0.59	42	0.80	68	0.69	68	0.63	62	0.77
29	0.67	26	0.57	43	0.78	75	0.68	82	0.61	55	0.74
56	0.65	53	0.53	29	0.78	26	0.67	83	0.59	5	0.73
59	-0.36	46	-0.45	69	-0.40	49	-0.53	1	-0.47	50	-0.43
44	-0.37	99	-0.45	54	-0.44	1	-0.55	46	-0.52	1	-0.45
57	-0.45	80	-0.46	47	-0.44	85	-0.58	50	-0.53	47	-0.54
4	-0.45	77	-0.50	57	-0.62	50	-0.58	49	-0.60	57	-0.72
69	-0.55	85	-0.53	4	-0.64	46	-0.64	85	-0.69	4	-0.76
43) H2		44) H3		45) H4		46) B1		47) B2		48) CCK1	
39	0.78	69	0.42	58	0.56	50	0.78	46	0.76	67	0.67
5	0.76	12	0.39	89	0.54	47	0.76	4	0.66	75	0.53
72	0.73	9	0.39	35	0.53	85	0.70	57	0.63	41	0.52
37	0.73	4	0.36	31	0.53	4	0.68	50	0.61	53	0.49
11	0.70	20	0.29	61	0.52	57	0.66	6	0.53	58	0.46
80	-0.30	16	-0.31	86	-0.19	36	-0.62	62	-0.50	46	-0.26
47	-0.35	29	-0.32	98	-0.24	40	-0.64	52	-0.52	50	-0.33
69	-0.42	55	-0.33	56	-0.24	75	-0.69	30	-0.54	85	-0.34
4	-0.50	37	-0.37	85	-0.30	68	-0.69	42	-0.54	49	-0.35
57	-0.50	97	-0.38	49	-0.31	32	-0.70	7	-0.59	98	-0.38

**Table 2 The five strongest positive and negative correlations of each receptor with other receptors, calculated using 169 brain regions (Continued)**

49) CCK2		50) CRF1		51) CRF2		52) Gal1		53) Gal2		54) Gal3	
85	0.93	1	0.80	14	0.40	15	0.61	75	0.75	64	0.62
56	0.78	46	0.78	85	0.39	68	0.61	73	0.67	78	0.56
77	0.71	4	0.76	86	0.34	60	0.59	41	0.65	100	0.56
98	0.67	57	0.74	49	0.31	73	0.57	83	0.64	24	0.55
46	0.63	98	0.71	22	0.30	32	0.57	82	0.63	89	0.55
41	-0.60	40	-0.58	94	-0.29	57	-0.52	50	-0.48	39	-0.44
75	-0.67	94	-0.61	36	-0.29	1	-0.53	46	-0.49	85	-0.44
100	-0.69	68	-0.66	75	-0.33	50	-0.56	49	-0.58	29	-0.48
12	-0.70	75	-0.68	41	-0.34	46	-0.56	98	-0.59	49	-0.54
66	-0.71	32	-0.76	68	-0.41	4	-0.58	85	-0.63	56	-0.63
55) MCH1		56) MCH2		57) MC1		58) MC2		59) MC3		60) MC4	
30	0.80	29	0.87	4	0.93	45	0.56	60	0.34	52	0.59
29	0.78	49	0.78	50	0.74	35	0.54	69	0.29	32	0.56
42	0.74	30	0.76	1	0.71	61	0.53	44	0.27	68	0.56
39	0.72	39	0.75	46	0.66	31	0.51	41	0.26	75	0.55
56	0.71	86	0.74	47	0.63	100	0.47	84	0.24	15	0.47
47	-0.29	12	-0.43	15	-0.60	86	-0.18	2	-0.24	98	-0.38
44	-0.33	100	-0.44	39	-0.62	56	-0.21	23	-0.24	1	-0.40
69	-0.36	64	-0.46	76	-0.65	85	-0.25	90	-0.25	47	-0.44
57	-0.50	66	-0.55	30	-0.71	98	-0.25	3	-0.26	50	-0.45
4	-0.52	54	-0.63	42	-0.72	49	-0.25	37	-0.36	46	-0.54
61) MC5		62) Y1		63) Y2		64) Y4		65) Y5		66) Y6	
88	0.55	65	0.93	7	0.59	54	0.62	62	0.93	100	0.66
31	0.54	42	0.77	42	0.53	100	0.59	5	0.80	75	0.63
58	0.53	5	0.73	62	0.51	96	0.57	33	0.79	12	0.61
45	0.52	39	0.70	65	0.50	89	0.57	11	0.74	82	0.58
6	0.51	33	0.67	30	0.45	24	0.55	39	0.73	36	0.57
11	-0.12	46	-0.39	46	-0.34	85	-0.33	46	-0.38	46	-0.45
90	-0.14	50	-0.43	57	-0.40	30	-0.36	50	-0.44	77	-0.51
98	-0.14	47	-0.50	50	-0.41	49	-0.39	47	-0.49	56	-0.55
91	-0.14	57	-0.57	47	-0.47	86	-0.40	57	-0.54	85	-0.70
22	-0.16	4	-0.64	4	-0.51	56	-0.46	4	-0.59	49	-0.71
67) NT1		68) NT2		69) $\mu$		70) $\delta$		71) $\kappa$		72) ORL-1	
48	0.67	75	0.81	4	0.49	43	0.61	72	0.52	5	0.82
75	0.65	94	0.77	57	0.44	22	0.60	62	0.51	7	0.76
68	0.64	40	0.69	44	0.42	37	0.59	65	0.48	18	0.76
82	0.57	12	0.67	1	0.39	56	0.58	5	0.46	39	0.74
41	0.56	32	0.64	9	0.39	90	0.57	17	0.45	43	0.73
85	-0.40	57	-0.56	42	-0.40	66	-0.25	50	-0.13	80	-0.40
50	-0.46	4	-0.57	39	-0.40	83	-0.27	46	-0.18	47	-0.47
46	-0.48	85	-0.61	43	-0.42	53	-0.28	4	-0.18	46	-0.53
57	-0.48	50	-0.66	22	-0.45	4	-0.28	57	-0.19	57	-0.58
4	-0.49	46	-0.69	37	-0.55	69	-0.39	14	-0.19	4	-0.60

**Table 2 The five strongest positive and negative correlations of each receptor with other receptors, calculated using 169 brain regions (Continued)**

73) OX1		74) OX2		75) OT		76) SST1		77) SST2		78) SST3	
83	0.69	53	0.54	68	0.81	42	0.72	99	0.77	100	0.78
53	0.67	41	0.53	41	0.80	62	0.66	49	0.71	82	0.73
75	0.64	8	0.52	53	0.75	39	0.64	85	0.70	24	0.69
19	0.63	73	0.50	82	0.72	30	0.62	34	0.59	79	0.66
41	0.57	38	0.48	32	0.70	65	0.61	80	0.57	40	0.66
1	-0.39	92	-0.35	98	-0.59	1	-0.41	12	-0.50	34	-0.47
85	-0.45	50	-0.36	49	-0.67	46	-0.43	93	-0.50	77	-0.49
46	-0.48	77	-0.39	50	-0.68	50	-0.46	66	-0.51	46	-0.49
50	-0.51	98	-0.41	46	-0.69	57	-0.65	95	-0.53	49	-0.53
98	-0.53	85	-0.43	85	-0.73	4	-0.68	100	-0.54	85	-0.59
79) SST4		80) SST5		81) NK1		82) NK2		83) NK3		84) TRHR	
24	0.67	50	0.61	40	0.66	100	0.77	73	0.69	16	0.52
78	0.66	85	0.59	27	0.59	78	0.73	53	0.64	67	0.51
100	0.60	46	0.58	94	0.57	75	0.72	75	0.64	32	0.51
82	0.58	77	0.57	12	0.57	40	0.65	82	0.64	75	0.51
2	0.54	4	0.56	82	0.57	83	0.64	41	0.59	83	0.50
77	-0.17	18	-0.43	4	-0.36	4	-0.42	49	-0.54	49	-0.38
57	-0.18	23	-0.44	57	-0.36	50	-0.44	46	-0.54	50	-0.38
4	-0.20	38	-0.46	1	-0.40	49	-0.54	50	-0.55	85	-0.38
49	-0.25	75	-0.46	50	-0.46	46	-0.59	85	-0.57	98	-0.40
85	-0.29	36	-0.47	46	-0.49	85	-0.63	98	-0.58	46	-0.43
85) VPAC1		86) VPAC2		87) V1a		88) V1b		89) V2		90) A1	
49	0.93	29	0.80	76	0.46	6	0.63	100	0.65	3	0.72
77	0.70	56	0.74	19	0.44	61	0.55	78	0.63	98	0.59
46	0.70	30	0.67	7	0.40	31	0.48	24	0.57	70	0.57
98	0.68	55	0.62	32	0.40	58	0.43	64	0.57	43	0.53
50	0.65	22	0.62	52	0.39	96	0.38	54	0.55	39	0.53
12	-0.67	66	-0.35	50	-0.32	30	-0.22	98	-0.34	84	-0.34
41	-0.69	4	-0.36	46	-0.33	39	-0.23	77	-0.37	53	-0.34
66	-0.70	69	-0.38	57	-0.36	62	-0.25	56	-0.39	73	-0.34
75	-0.73	64	-0.40	4	-0.36	22	-0.26	85	-0.47	32	-0.36
100	-0.74	54	-0.42	47	-0.39	23	-0.26	49	-0.50	83	-0.39
91) A2A		92) A2B		93) A3		94) P2Y1		95) P2Y2		96) P2Y4	
13	0.68	9	0.57	23	0.68	68	0.77	100	0.58	64	0.57
21	0.65	99	0.51	100	0.59	32	0.63	23	0.55	24	0.52
11	0.55	22	0.46	41	0.57	27	0.63	40	0.54	79	0.47
27	0.53	56	0.45	97	0.56	21	0.58	12	0.49	89	0.44
12	0.53	49	0.44	78	0.55	81	0.57	38	0.49	54	0.43
10	-0.25	53	-0.28	99	-0.37	57	-0.45	99	-0.46	86	-0.17
55	-0.25	100	-0.31	34	-0.43	4	-0.46	34	-0.47	62	-0.18
87	-0.25	66	-0.34	49	-0.48	1	-0.48	77	-0.53	42	-0.18
19	-0.27	54	-0.34	77	-0.50	46	-0.55	49	-0.54	30	-0.19
76	-0.29	74	-0.35	85	-0.53	50	-0.61	85	-0.54	87	-0.23

**Table 2 The five strongest positive and negative correlations of each receptor with other receptors, calculated using 169 brain regions (Continued)**

97) P2Y6		98) P2Y11		99) CB1		100) CB2	
2	0.60	50	0.71	77	0.77	78	0.78
23	0.59	85	0.68	49	0.54	82	0.77
93	0.56	49	0.67	85	0.53	40	0.70
15	0.49	46	0.64	92	0.51	12	0.66
3	0.48	1	0.63	80	0.46	66	0.66
1	-0.31	73	-0.53	93	-0.37	46	-0.49
80	-0.36	83	-0.58	23	-0.38	34	-0.54
44	-0.38	75	-0.59	100	-0.38	77	-0.54
57	-0.45	53	-0.59	38	-0.45	49	-0.69
4	-0.50	32	-0.64	95	-0.46	85	-0.74

The receptor numbers (Table 1) are given in the left column and the correlations in the right column (e.g., mGluR1 has the strongest positive correlation with CRF1 (0.80)). Correlations with an absolute value of less than 0.34 are not significant after the Bonferroni correction (at  $\alpha = 0.05$ ) and should be interpreted with caution. The actual correlations may be somewhat stronger due to the imperfect reliability of the expression data (the statistical "attenuation" phenomenon). For compactness, the following abbreviations were used: GABA1 = GABABR1, GABA2 = GABABR2.

disorders [63,65,66]. The exact structure of the communities is likely to become more refined as more data become available in the Allen Brain Atlas. In general, receptor network analyses hold great promise for understanding the brain in health and disease, as has been demonstrated by recent research [36,67-69].

The relatively simple distribution of correlations (Figure 3) raises interesting questions. Theoretically, such a distribution can be obtained from a single dynamical interaction. Depending on the numerical values of its coefficients, the same process can produce uncorrelated or highly correlated equilibrium values, even if the two receptors are strongly dynamically coupled [70]. Since theoretically all receptors can be expressed by all brain cells and they can only differ in their equilibrium levels (some mRNA amounts may be undetectably small), such qualitative uniformity remains an intriguing possibility.

## Conclusions

Progress in neuroscience requires both accurate factual observations and complexity reduction. Since information processing in the brain depends on thousands of unique neurotransmitter-receptor interactions, understanding how these neurotransmitter-receptor pairs operate in functional groups is not only a theoretical imperative, but also a practical necessity. The obtained results suggest that the apparent complexity of neurotransmitter signaling has an underlying global structure, which is not readily detectable if receptor interactions are studied in isolation.


## Methods

The human brain expression data of one hundred G protein-coupled neurotransmitter receptors (Table 1) were


downloaded from the Allen Brain Atlas data portal (<http://human.brain-map.org>; the data release of March 7, 2013). Technical details about the brain donors, tissue preparation, specificity controls, and data normalization (including normalization across brains) are described in the Allen Human Brain Atlas Technical White Papers (Case Qualification and Donor Profiles, Microarray Survey, Microarray Data Normalization).

The normalized mRNA amounts in 169 brain regions were obtained from six available subjects (three Caucasian males (31, 55, and 57 years of age), two African-American males (24 and 39 years of age), and one Hispanic female (49 years of age)).


Of the analyzed regions, the 14 regions from the myelencephalon were the central glial substance, the arcuate nucleus of the medulla, the inferior olivary complex, the gracile nucleus, the cuneate nucleus, the raphe nuclei of the medulla, the central medullary reticular group, the lateral medullary reticular group, the gigantocellular group, the hypoglossal nucleus, the dorsal motor nucleus of the vagus, the spinal trigeminal nucleus, the vestibular nuclei, and the cochlear nuclei. The 12 regions from the pontine tegmentum were the pontine nuclei, the superior olivary complex, the central gray of the pons, the paramedian pontine reticular formation, the locus ceruleus, the nucleus subceruleus, the pontine raphe nucleus, the medial parabrachial nucleus, the lateral parabrachial nucleus, the facial motor nucleus, the abducens nucleus, and the trigeminal nuclei. The 27 regions from the cerebellum were 12 vermal areas (I-II, III, IV, V, VI, VIIA, VIIAt, VIIB, VIIIA, VIIIB, IX, X), 11 lobules (III, IV, V, VI, Crus I, Crus II, VIIB, VIIIA, VIIIB, IX, X), and the four deep cerebellar nuclei (the fastigial nucleus, the globose nucleus, the emboliform nucleus, and the dentate



**Figure 3** The statistical distributions of all correlations and their subsets. **A, B**, The distribution of all correlations and their approximations with the normal distribution (**A**) and the beta distribution (**B**). Both theoretical distributions have the sample mean and variance. **C**, The distribution of the correlations between receptors that represent the same neurotransmitter (in different pairs, the neurotransmitters may be different). **D**, The distribution of the correlations between receptors that represent different neurotransmitters. **E**, The distribution of the correlations between receptors that have the same G protein-coupling (in different pairs, the couplings may be different). **F**, The distribution of the correlations between receptors that have different G protein-couplings. **G**, The distribution of the correlations of a simulated sample of 100 sets, each of which contains 169 independent, normally distributed numbers (with mean = 0 and standard deviation = 1). The simulation shows that the distribution of the correlations between G protein-coupled receptors is different from what would be expected from a matching sample of uncorrelated sets.




**Figure 4 Graph representations of receptor correlations. A**, A graph representation of all significant correlations between receptors (after the Bonferroni correction; all Cook's distances do not exceed 1.0). The inset shows the distribution of the vertex degrees. **B**, The neighborhood subgraph of the nociceptin receptor (OPRL1); marked in the center.



nucleus). The 14 regions from the mesencephalon were the ventral tegmental area, the substantia nigra, the red nucleus, the central gray of the midbrain, the midbrain raphe nuclei, the midbrain reticular formation, the trochlear nucleus, the oculomotor nuclear complex, the Edinger-Westphal nucleus, the inferior colliculus, the superior colliculus, the pretectal region, the interstitial nucleus of Cajal, and the nucleus of Darkschewitsch. The 11 regions from the thalamic area were the subthalamus, the ventral thalamus, the posterior group of nuclei, the medial geniculate complex, the dorsal lateral geniculate nucleus, the dorsal division of the lateral group of nuclei, the ventral division of the lateral group of nuclei, the anterior group of nuclei, the medial group of nuclei, the caudal group of intralaminar nuclei, and the rostral group of intralaminar nuclei. The 19 regions from the epithalamus and the hypothalamus were the pineal, the habenular

nuclei, the paraventricular thalamic nuclei, the posterior hypothalamic area, the lateral hypothalamic area, the mammillary region of the lateral hypothalamic area, the mammillary body, the supramammillary nucleus, the tuberomammillary nucleus, the tuberal region of the lateral hypothalamic area, the lateral tuberal nucleus, the perifornical nucleus, the ventromedial hypothalamic nucleus, the dorsomedial hypothalamic nucleus, the anterior hypothalamic area, the arcuate nucleus of the hypothalamus, the preoptic region, the paraventricular nucleus of the hypothalamus, and the supraoptic nucleus. The 9 regions from the striatum, pallidum, and septum were the head of the caudate nucleus, the body of the caudate nucleus, the tail of the caudate nucleus, the nucleus accumbens, the putamen, the external segment of the globus pallidus, the internal segment of the globus pallidus, the substantia innominata, and the septal nuclei. The 6



**Figure 6** The two communities of G protein-coupled neurotransmitter receptors detected with the clique percolation method. The absolute values of correlations were thresholded at 0,6 (with the corresponding  $p < 10^{-15}$ ) and the clique number was set at  $k = 4$ .

regions from the amygdala were the central nucleus, the basomedial nucleus, the cortico-medial area, the basolateral nucleus, the lateral nucleus, and the amygdaloid transition zone. Two other regions from the lateral pallium were the claustrum and the piriform cortex. The 7 regions from the hippocampal formation were the parahippocampal gyrus, the dentate gyrus, the CA1 field, the CA2 field, the CA3 field, the CA4 field, and the subiculum. The cingulate gyrus was subdivided into the frontal, parietal, and retrosplenial parts, and the insula was subdivided into the short and long gyri. The 9 regions from the temporal lobe were the temporal pole, planum polare, the transverse gyri, Heschl's gyrus, the planum temporale, the superior temporal gyrus, the middle temporal gyrus, the inferior temporal gyrus, and the fusiform gyrus. The 6 regions from the occipital lobe were the occipital pole, the cuneus, the lingual gyrus, the superior occipital gyrus, the inferior occipital gyrus, and the occipito-temporal gyrus. The 6 regions from the parietal lobe were the precuneus, the posterior paracentral lobule, superior parietal lobule, the angular gyrus, the supramarginal gyrus, and the

postcentral gyrus. The 19 regions from the frontal lobe were the paraterminal gyrus, the subcallosal gyrus, the parolfactory gyri, the anterior paracentral lobule, the precentral gyrus, the superior frontal gyrus, the middle frontal gyrus, the frontal operculum, the opercular part of the inferior frontal gyrus, the triangular part of the inferior frontal gyrus, the orbital part of the inferior frontal gyrus, the lateral orbital gyrus, the medial orbital gyrus, the posterior orbital gyrus, the anterior orbital gyrus, the gyrus rectus, the superior rostral gyrus, the inferior rostral gyrus, and the frontal pole. In addition, the expression data from the cingulum, the corpus callosum, and the choroid plexus of the lateral ventricle were used.

Expression data were available from four or more subjects in 86% of the 169 brain regions, and 53% of the 169 brain regions were represented by all six subjects. Only four brain regions (2%) were represented by a single subject. The median number of mRNA probes per gene was 3. One gene was analyzed with only one probe (ADORA2B) and one gene was analyzed with 89 probes (CNR1). Probes were located on different exons as much



as possible when multiple probes were used for a gene (Allen Human Brain Atlas Technical White Paper: Microarray Survey).

The data were analyzed in Mathematica 9 (Wolfram Research, Inc.). The mean expression values of each brain region of each subject were obtained by averaging all probes, and the inter-subject variability was assessed by calculating the cross-correlations between all subject pairs (15 correlations; the median values are given in Table 1). Next, the overall mean values of each brain region were obtained by averaging all available subjects, and the correlations between all unique receptor pairs (4950) were calculated. In all correlation calculations, all 169 brain regions were used as the data points. For this sample size, a correlation of  $\pm 0.16$  is significant with  $p < 0.05$  and a correlation of  $\pm 0.34$  is significant with  $p < 0.05/4950$  (i.e., it is significant after the Bonferroni correction for the multiple tests).

In graph analyses, two receptors were considered to be connected by an edge only if their correlation was significant after the Bonferroni correction (i.e., if  $p < 0.05/4950$ ) and, additionally, if all Cook's distances in the linear regression model did not exceed 1.0 (to avoid the effect of influential outliers).

Functional receptor communities were analyzed using the modularity algorithm implemented in Mathematica 9 and the clique percolation method implemented in CFinder (<http://www.cfinder.org>) and based on a published algorithm [42].

The Mathematica notebooks are available in Additional file 1 and Additional file 2.

## Additional files

**Additional file 1: The analysis of a single receptor.** The code to process the mRNA expression data of a single neurotransmitter receptor.

**Additional file 2: The analysis of all receptors.** The code to analyze the mRNA expression associations among all neurotransmitter receptors.

## Competing interests

The author declares that he has no competing interests.

## Acknowledgements

This work was supported by UCSB Academic Senate Research Grants and the UCSB Open Access Fund Pilot Program.

Received: 22 July 2013 Accepted: 30 December 2013

Published: 17 January 2014

## References

- Henny P, Brown MT, Micklem BR, Magill PJ, Bolam JP: **Stereological and ultrastructural quantification of the afferent synaptome of individual neurons.** *Brain Struct Funct* 2013. in press.
- Stenberg D, Litonius E, Halldner L, Johansson B, Fredholm BB, Porkka-Heiskanen T: **Sleep and its homeostatic regulation in mice lacking the adenosine A<sub>1</sub> receptor.** *J Sleep Res* 2003, **12**:283–290.
- Johansson B, Halldner L, Dunwiddie TV, Masino SA, Poelchen W, Gimenez-Llort L, Escorihuela RM, Fernandez-Teruel A, Wiesenfeld-Hallin Z, Xu XJ, Hardemark A, Betsholtz C, Herlenius E, Fredholm BB: **Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A<sub>1</sub> receptor.** *Proc Natl Acad Sci USA* 2001, **98**:9407–9412.
- Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El YM, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M: **Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A<sub>2a</sub> receptor.** *Nature* 1997, **388**:674–678.
- Chruscinski AJ, Rohrer DK, Schauble E, Desai KH, Bernstein D, Kobilka BK: **Targeted disruption of the  $\beta_2$  adrenergic receptor gene.** *J Biol Chem* 1999, **274**:16694–16700.
- Heisler LK, Chu HM, Brennan TJ, Danao JA, Bajwa P, Parsons LH, Tecott LH: **Elevated anxiety and antidepressant-like responses in serotonin 5-HT<sub>1A</sub> receptor mutant mice.** *Proc Natl Acad Sci USA* 1998, **95**:15049–15054.
- Weisstaub NV, Zhou M, Lira A, Lambe E, Gonzalez-Maeso J, Hornung JP, Sibille E, Underwood M, Itohara S, Dauer WT, Ansorge MS, Morelli E, Mann JJ, Toth M, Aghajanian G, Sealfon SC, Hen R, Gingrich JA: **Cortical 5-HT<sub>2A</sub> receptor signaling modulates anxiety-like behaviors in mice.** *Science* 2006, **313**:536–540.
- Compan V, Zhou M, Grailhe R, Gazzara RA, Martin R, Gingrich J, Dumuis A, Brunner D, Bockaert J, Hen R: **Attenuated response to stress and novelty and hypersensitivity to seizures in 5-HT<sub>4</sub> receptor knock-out mice.** *J Neurosci* 2004, **24**:412–419.
- Yokoi M, Kobayashi K, Manabe T, Takahashi T, Sakaguchi I, Katsuura G, Shigemoto R, Ohishi H, Nomura S, Nakamura K, Nakao K, Katsuki M, Nakanishi S: **Impairment of hippocampal mossy fiber LTD in mice lacking mGluR<sub>2</sub>.** *Science* 1996, **273**:645–647.
- Xu M, Koeltzow TE, Santiago GT, Moratalla R, Cooper DC, Hu XT, White NM, Graybiel AM, White FJ, Tonegawa S: **Dopamine D<sub>3</sub> receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D<sub>1</sub> and D<sub>2</sub> receptors.** *Neuron* 1997, **19**:837–848.
- Segu L, Lecomte MJ, Wolff M, Santamaria J, Hen R, Dumuis A, Berrard S, Bockaert J, Buhot MC, Compan V: **Hyperfunction of muscarinic receptor maintains long-term memory in 5-HT<sub>4</sub> receptor knock-out mice.** *PLoS One* 2010, **5**:e9529.
- Jacobs BL, Azmitia EC: **Structure and function of the brain serotonin system.** *Physiol Rev* 1992, **72**:165–229.
- Duvernoy HM, Delon S, Vannson JL: **Cortical blood vessels of the human brain.** *Brain Res Bull* 1981, **7**:519–579.
- Cavaglia M, Dombrowski SM, Drazba J, Vasanji A, Bokesch PM, Janigro D: **Regional variation in brain capillary density and vascular response to ischemia.** *Brain Res* 2001, **910**:81–93.
- Hendricks TJ, Fyodorov DV, Wegman LJ, Lelutiu NB, Pehek EA, Yamamoto B, Silver J, Weeber EJ, Sweatt JD, Deneris ES: **Pet-1 ETS gene plays a critical role in 5-HT neuron development and is required for normal anxiety-like and aggressive behavior.** *Neuron* 2003, **37**:233–247.
- Gutknecht L, Araragi N, Merker S, Waider J, Sommerlandt FM, Mlinar B, Baccini G, Mayer U, Proft F, Hamon M, Schmitt AG, Corradetti R, Lanfumey L, Lesch KP: **Impacts of brain serotonin deficiency following Tph2 inactivation on development and raphe neuron serotonergic specification.** *PLoS One* 2012, **7**:e43157.
- Migliarini S, Pacini G, Pelosi B, Lunardi G, Pasqualetti M: **Lack of brain serotonin affects postnatal development and serotonergic neuronal circuitry formation.** *Mol Psychiatry* 2013, **18**:1106–1118.
- Vitalis T, Cases O, Passemard S, Callebert J, Parnavelas JG: **Embryonic depletion of serotonin affects cortical development.** *Eur J Neurosci* 2007, **26**:331–344.
- Ross GW, Petrovitch H, Abbott RD, Nelson J, Markesbery W, Davis D, Hardman J, Launer L, Masaki K, Tanner CM, White LR: **Parkinsonian signs and substantia nigra neuron density in decedents elders without PD.** *Ann Neurol* 2004, **56**:532–539.
- Bruno JP, Snyder AM, Stricker EM: **Effect of dopamine-depleting brain lesions on suckling and weaning in rats.** *Behav Neurosci* 1984, **98**:156–161.
- Castaneda E, Whishaw IQ, Lerner L, Robinson TE: **Dopamine depletion in neonatal rats: effects on behavior and striatal dopamine release assessed by intracerebral microdialysis during adulthood.** *Brain Res* 1990, **508**:30–39.
- Robertson D, Haile V, Perry SE, Robertson RM, Phillips JA III, Biaggioni I: **Dopamine beta-hydroxylase deficiency. A genetic disorder of cardiovascular regulation.** *Hypertension* 1991, **18**:1–8.

23. Timmers HJ, Deinum J, Wevers RA, Lenders JW: **Congenital dopamine-beta-hydroxylase deficiency in humans.** *Ann N Y Acad Sci* 2004, **1018**:520–523.
24. Arcelli P, Frassoni C, Regondi MC, De BS, Spreafico R: **GABAergic neurons in mammalian thalamus: a marker of thalamic complexity?** *Brain Res Bull* 1997, **42**:27–37.
25. Sherman SM, Guillery RW: *Exploring the Thalamus and Its Role in Cortical Function.* Cambridge: The MIT Press; 2006.
26. Yamazoe I, Takeuchi Y, Matsushita H, Kawano H, Sawada T: **Serotonergic heterotypic sprouting in the unilaterally dopamine-depleted mouse neostriatum.** *Dev Neurosci* 2001, **23**:78–83.
27. Martin P, Ohno M, Southerland SB, Mailman RB, Suzuki K: **Heterotypic sprouting of serotonergic forebrain fibers in the brindled mottled mutant mouse.** *Brain Res Dev Brain Res* 1994, **77**:215–225.
28. Thomas SA, Matsumoto AM, Palmiter RD: **Noradrenaline is essential for mouse fetal development.** *Nature* 1995, **374**:643–646.
29. Dulcis D, Jamshidi P, Leutgeb S, Spitzer NC: **Neurotransmitter switching in the adult brain regulates behavior.** *Science* 2013, **340**:449–453.
30. Albizu L, Moreno JL, Gonzalez-Maeso J, Sealfon SC: **Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics.** *CNS Neurol Disord Drug Targets* 2010, **9**:636–650.
31. Rozenfeld R, Bushlin I, Gomes I, Tzavaras N, Gupta A, Neves S, Battini L, Gusella GL, Lachmann A, Ma'ayan A, Blitzer RD, Devi LA: **Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons.** *PLoS One* 2012, **7**:e29239.
32. Fribourg M, et al: **Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs.** *Cell* 2011, **147**:1011–1023.
33. Albizu L, Holloway T, Gonzalez-Maeso J, Sealfon SC: **Functional crosstalk and heteromerization of serotonin 5-HT<sub>2A</sub> and dopamine D<sub>2</sub> receptors.** *Neuropharmacology* 2011, **61**:770–777.
34. Lohse MJ: **Dimerization in GPCR mobility and signaling.** *Curr Opin Pharmacol* 2010, **10**:53–58.
35. Janušonis S: **Relationships among variables and their equilibrium values: caveats of time-less interpretation.** *Biol Rev Camb Philos Soc* 2012, **87**:275–289.
36. Wang SS, Kamphuis W, Huitinga I, Zhou JN, Swaab DF: **Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances.** *Mol Psychiatry* 2008, **13**:786–799. 741.
37. Templin JS, Bang SJ, Soiza-Reilly M, Berde CB, Commons KG: **Patterned expression of ion channel genes in mouse dorsal raphe nucleus determined with the Allen Mouse Brain Atlas.** *Brain Res* 2012, **1457**:1–12.
38. Ayoub AE, Oh S, Xie Y, Leng J, Cotney J, Dominguez MH, Noonan JP, Rakic P: **Transcriptional programs in transient embryonic zones of the cerebral cortex defined by high-resolution mRNA sequencing.** *Proc Natl Acad Sci USA* 2011, **108**:14950–14955.
39. Ball S, Gilbert TL, Overly CC: **The human brain online: an open resource for advancing brain research.** *PLoS Biol* 2012, **10**:e1001453.
40. Shen EH, Overly CC, Jones AR: **The Allen Human Brain Atlas: comprehensive gene expression mapping of the human brain.** *Trends Neurosci* 2012, **35**:711–714.
41. Sonawane AR, Bhattacharyay A, Santhanam MS, Ambika G: **Evolving networks with bimodal degree distribution.** *Eur Physical J B* 2012, **85**:118.
42. Palla G, Derenyi I, Farkas I, Vicsek T: **Uncovering the overlapping community structure of complex networks in nature and society.** *Nature* 2005, **435**:814–818.
43. Lichter JB, Barr CL, Kennedy JL, Van Tol HH, Kidd KK, Livak KJ: **A hypervariable segment in the human dopamine receptor D4 (DRD4) gene.** *Hum Mol Genet* 1993, **2**:767–773.
44. Ebstein RP, Novick O, Umansky R, Priel B, Osher Y, Blaine D, Bennett ER, Nemanov L, Katz M, Belmaker RH: **Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking.** *Nat Genet* 1996, **12**:78–80.
45. Wang E, Ding YC, Flodman P, Kidd JR, Kidd KK, Grady DL, Ryder OA, Spence MA, Swanson JM, Moyzis RK: **The genetic architecture of selection at the human dopamine receptor D4 (DRD4) gene locus.** *Am J Hum Genet* 2004, **74**:931–944.
46. Sasaki JY, Kim HS, Mojaverian T, Kelley LD, Park IY, Janušonis S: **Religion priming differentially increases prosocial behavior among variants of the dopamine D4 receptor (DRD4) gene.** *Soc Cogn Affect Neurosci* 2013, **8**:209–215.
47. Ding YC, Chi HC, Grady DL, Morishima A, Kidd JR, Kidd KK, Flodman P, Spence MA, Schuck S, Swanson JM, Zhang YP, Moyzis RK: **Evidence of positive selection acting at the human dopamine receptor D4 gene locus.** *Proc Natl Acad Sci USA* 2002, **99**:309–314.
48. Simpson J, Vetuz G, Wilson M, Brookes KJ, Kent L: **The DRD4 receptor Exon 3 VNTR and 5' SNP variants and mRNA expression in human post-mortem brain tissue.** *Am J Med Genet B Neuropsychiatr Genet* 2010, **153B**:1228–1233.
49. Schwanhauser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M: **Global quantification of mammalian gene expression control.** *Nature* 2011, **473**:337–342.
50. Luttrell LM, Gesty-Palmer D: **Beyond desensitization: physiological relevance of arrestin-dependent signaling.** *Pharmacol Rev* 2010, **62**:305–330.
51. Claeysen S, Sebben M, Becamel C, Bockaert J, Dumuis A: **Novel brain-specific 5-HT<sub>4</sub> receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain.** *Mol Pharmacol* 1999, **55**:910–920.
52. Mnie-Filali O, Amraei MG, Benmbarek S, Archer-Lahlou E, Penas-Cazorla R, Vilario MT, Boye SM, Pineyro G: **Serotonin 4 receptor (5-HT<sub>4</sub>R) internalization is isoform-specific: effects of 5-HT and RS67333 on isoforms A and B.** *Cell Signal* 2010, **22**:501–509.
53. Salom D, Wang B, Dong Z, Sun W, Padayatti P, Jordan S, Salon JA, Palczewski K: **Post-translational modifications of the serotonin type 4 receptor heterologously expressed in mouse rod cells.** *Biochemistry* 2012, **51**:214–224.
54. Sen N, Snyder SH: **Protein modifications involved in neurotransmitter and gasotransmitter signaling.** *Trends Neurosci* 2010, **33**:493–502.
55. Kursawe R, Paschke R: **Modulation of TSHR signaling by posttranslational modifications.** *Trends Endocrinol Metab* 2007, **18**:199–207.
56. Delille HK, Mezler M, Marek GJ: **The two faces of the pharmacological interaction of mGlu<sub>2</sub> and 5-HT<sub>2A</sub> - Relevance of receptor heterocomplexes and interaction through functional brain pathways.** *Neuropharmacology* 2013, **70**:296–305.
57. Rozenfeld R, Devi LA: **Receptor heteromerization and drug discovery.** *Trends Pharmacol Sci* 2010, **31**:124–130.
58. Rozenfeld R, Devi LA: **Exploring a role for heteromerization in GPCR signalling specificity.** *Biochem J* 2011, **433**:11–18.
59. Gonzalez-Maeso J, Sealfon SC: **Psychedelics and schizophrenia.** *Trends Neurosci* 2009, **32**:225–232.
60. Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC: **Identification of a serotonin/glutamate receptor complex implicated in psychosis.** *Nature* 2008, **452**:93–97.
61. Kurita M, Moreno JL, Holloway T, Kozlenkov A, Mucci G, Garcia-Bea A, Hanks JB, Neve R, Nestler EJ, Russo SJ, Gonzalez-Maeso J: **Repressive epigenetic changes at the mGlu<sub>2</sub> promoter in frontal cortex of 5-HT<sub>2A</sub> knockout mice.** *Mol Pharmacol* 2013, **83**:1166–1175.
62. Brown RE, Basheer R, McKenna JT, Strecker RE, McCarley RW: **Control of sleep and wakefulness.** *Physiol Rev* 2012, **92**:1087–1187.
63. Celada P, Puig MV, Martin-Ruiz R, Casanovas JM, Artigas F: **Control of the serotonergic system by the medial prefrontal cortex: potential role in the etiology of PTSD and depressive disorders.** *Neurotox Res* 2002, **4**:409–419.
64. Lucas G, Compan V, Charnay Y, Neve RL, Nestler EJ, Bockaert J, Barrot M, Debonnel G: **Frontocortical 5-HT(4) receptors exert positive feedback on serotonergic activity: Viral transfections, subacute and chronic treatments with 5-HT(4) agonists.** *Biol Psychiatry* 2005, **57**:918–925.
65. Lucas G, Rymar VV, Du J, Mnie-Filali O, Bisgaard C, Manta S, Lambas-Senas L, Wiborg O, Haddjeri N, Pineyro G, Sadikot AF, Debonnel G: **Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action.** *Neuron* 2007, **55**:712–725.
66. Vollenweider FX, Kometer M: **The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.** *Nat Rev Neurosci* 2010, **11**:642–651.
67. Hu VW, Addington A, Hyman A: **Novel autism subtype-dependent genetic variants are revealed by quantitative trait and subphenotype**

association analyses of published GWAS data. *PLoS One* 2011, **6**:e19067.

68. Lee TL, Raygada MJ, Rennert OM: Integrative gene network analysis provides novel regulatory relationships, genetic contributions and susceptible targets in autism spectrum disorders. *Gene* 2012, **496**:88–96.
69. Lang UE, Borgwardt S: Molecular mechanisms of depression: perspectives on new treatment strategies. *Cell Physiol Biochem* 2013, **31**:761–777.
70. Janušonis S: Direct interaction with no correlation: an experimental pitfall in neural systems. *J Neurosci Methods* 2012, **206**:151–157.

doi:10.1186/1471-2202-15-16

**Cite this article as:** Janušonis: Functional associations among G protein-coupled neurotransmitter receptors in the human brain. *BMC Neuroscience* 2014 **15**:16.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

